CheckMate 649 3-Year Follow-up: Nivolumab Plus Chemotherapy for Gastric and Esophageal Cancers

3-year follow-up of CheckMate 649: nivolumab + chemotherapy in GC/GEJC/EAC

Geoffrey Y. Ku, MD, offers opinion on the practice-changing potential of the CheckMate-649 study

CheckMate 649: 1L nivo + chemotherapy improves OS

Jaffer Ajani, MD, considers results from the CheckMate 649 study presented at ESMO 2020

CheckMate 649, un approfondimento sul follow-up a 4 anni

NIVO + chemo vs chemo as 1L treatment for advanced GC/GEJC/EAC: 4 year yr follow-up of CheckMate 649

Emerging Biomarkers and Novel Therapies for Esophageal Cancer

Expert Video Report on immunotherapy in gastro oesophageal cancer from 2021 ASCO Annual Meeting

September 26, 2024 Meeting of the Oncologic Drugs Advisory Committee (ODAC)

Advances in adjuvant and 1L immune checkpoint blockade for gastric and esophageal cancer

Adding Immunotherapy to First-Line Chemotherapy for Gastric Cancer: Data and Implications

#ESMO21 Expert Video Report on immunotherapy in gastro-oesophageal cancer

Understanding, Detecting, and Treating Gastroesophageal Junction Adenocarcinoma

Part 2 - Nivolumab with chemotherapy in advanced previously untreated Gastric - Dr. Anant Ramaswamy

Essential Updates in GI Immunotherapy: HCC and Esophageal Cancers

胃がんセミナー 松本 俊彦 先生（関西医科大学附属病院 がんセンター）OMCE #84

Viñeta ECA CheckMate 649, Nivolumab+QMT vs QMT

Clinical Trials Updates for Gastric Cancer Patients Webinar

Panel Discussion and Summary: Current and Future Gastroesophageal Cancer Treatments